CN104781256B - 3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途 - Google Patents

3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途 Download PDF

Info

Publication number
CN104781256B
CN104781256B CN201380056503.4A CN201380056503A CN104781256B CN 104781256 B CN104781256 B CN 104781256B CN 201380056503 A CN201380056503 A CN 201380056503A CN 104781256 B CN104781256 B CN 104781256B
Authority
CN
China
Prior art keywords
phenyl
alkyl
compound according
oxo
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380056503.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104781256A (zh
Inventor
卢克·格林
王海燕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN104781256A publication Critical patent/CN104781256A/zh
Application granted granted Critical
Publication of CN104781256B publication Critical patent/CN104781256B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201380056503.4A 2012-10-29 2013-10-25 3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途 Expired - Fee Related CN104781256B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12190319 2012-10-29
EP12190319.9 2012-10-29
PCT/EP2013/072361 WO2014067861A1 (en) 2012-10-29 2013-10-25 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel

Publications (2)

Publication Number Publication Date
CN104781256A CN104781256A (zh) 2015-07-15
CN104781256B true CN104781256B (zh) 2017-09-29

Family

ID=47143594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380056503.4A Expired - Fee Related CN104781256B (zh) 2012-10-29 2013-10-25 3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途

Country Status (23)

Country Link
US (1) US9611232B2 (enExample)
EP (1) EP2912034B1 (enExample)
JP (1) JP6216385B2 (enExample)
KR (1) KR20150075091A (enExample)
CN (1) CN104781256B (enExample)
AR (1) AR093168A1 (enExample)
AU (1) AU2013339607A1 (enExample)
BR (1) BR112015003996A2 (enExample)
CA (1) CA2879249A1 (enExample)
CL (1) CL2015000906A1 (enExample)
CO (1) CO7170170A2 (enExample)
CR (1) CR20150159A (enExample)
EA (1) EA026161B1 (enExample)
IL (1) IL237331A0 (enExample)
IN (1) IN2015DN00961A (enExample)
MA (1) MA38135B1 (enExample)
MX (1) MX2015002399A (enExample)
PE (1) PE20150775A1 (enExample)
PH (1) PH12015500292A1 (enExample)
SG (1) SG11201500585XA (enExample)
TW (1) TW201422596A (enExample)
UA (1) UA114649C2 (enExample)
WO (1) WO2014067861A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102047502B1 (ko) * 2016-06-20 2019-11-22 셀라이온바이오메드 주식회사 포타슘 채널 단백질을 이용한 암 진단용 조성물
WO2020193419A1 (en) 2019-03-22 2020-10-01 Saniona A/S Novel potassium channel inhibitors
US20240034717A1 (en) * 2020-09-22 2024-02-01 Saniona A/S Novel potassium channel inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831026A (en) * 1985-09-09 1989-05-16 Otsuka Pharmaceutical Co., Ltd. 2-oxa-isocephem compounds, compositions containing same and processes of using
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
CN1132201A (zh) * 1994-11-08 1996-10-02 默克专利股份有限公司 粘附受体拮抗剂
CN1329601A (zh) * 1998-12-04 2002-01-02 神经研究公司 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物
CN101160294A (zh) * 2005-02-22 2008-04-09 尼瑞斯药品公司 抗癌和抗微生物的噁唑烷酮以及类似物
US20080096918A1 (en) * 2004-12-15 2008-04-24 Sanofi-Aventis Deutschland Gmbh Novel cyclic ureas used as inhibitors of metalloproteases
CN102333782A (zh) * 2008-12-12 2012-01-25 雅培卫生保健产品有限责任公司 作为Kv1.3钾通道阻断剂的螺氮杂环庚烷-噁唑烷酮

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2538424C2 (de) * 1975-08-29 1983-01-05 Nordmark-Werke Gmbh, 2000 Hamburg 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat
AU1812197A (en) * 1996-03-01 1997-09-16 Sankyo Company Limited Hydroxamic acid derivatives
HK1049004A1 (en) * 2000-01-20 2003-04-25 Eisai Co., Ltd. Nitrogenous cyclic compounds and pharmaceutical compositions containing the same
JP3966693B2 (ja) * 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
JP4295505B2 (ja) * 2000-11-22 2009-07-15 バイエル アクチェンゲゼルシャフト 新規なラクタム置換ピラゾロピリジン誘導体
WO2006015159A2 (en) 2004-07-29 2006-02-09 Merck & Co., Inc. Potassium channel inhibitors
US20100056637A1 (en) 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2007109098A2 (en) * 2006-03-16 2007-09-27 Azevan Pharmaceuticals, Inc. HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS
WO2010123997A1 (en) * 2009-04-22 2010-10-28 Achaogen, Inc. Carbacephem beta-lactam antibiotics

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831026A (en) * 1985-09-09 1989-05-16 Otsuka Pharmaceutical Co., Ltd. 2-oxa-isocephem compounds, compositions containing same and processes of using
WO1992007567A1 (en) * 1990-11-06 1992-05-14 Smithkline Beecham Corporation Imidazolidinone compounds
CN1132201A (zh) * 1994-11-08 1996-10-02 默克专利股份有限公司 粘附受体拮抗剂
CN1329601A (zh) * 1998-12-04 2002-01-02 神经研究公司 作为离子通道调节剂的新的苯并咪唑啉酮一、苯并噁唑酮一或苯并噻唑啉酮衍生物
US20080096918A1 (en) * 2004-12-15 2008-04-24 Sanofi-Aventis Deutschland Gmbh Novel cyclic ureas used as inhibitors of metalloproteases
CN101160294A (zh) * 2005-02-22 2008-04-09 尼瑞斯药品公司 抗癌和抗微生物的噁唑烷酮以及类似物
CN102333782A (zh) * 2008-12-12 2012-01-25 雅培卫生保健产品有限责任公司 作为Kv1.3钾通道阻断剂的螺氮杂环庚烷-噁唑烷酮

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Acetylenic Carbamates as Potential Antitumour Agents;E. M. BESSELL,等;《Europ. J. Cancer》;19701231;第6卷;第483-488页 *

Also Published As

Publication number Publication date
PH12015500292A1 (en) 2015-04-20
MA38135A2 (fr) 2016-11-30
US9611232B2 (en) 2017-04-04
WO2014067861A1 (en) 2014-05-08
TW201422596A (zh) 2014-06-16
MA38135B1 (fr) 2018-11-30
EA201590729A1 (ru) 2015-07-30
CA2879249A1 (en) 2014-05-08
CL2015000906A1 (es) 2015-09-11
CR20150159A (es) 2015-04-30
SG11201500585XA (en) 2015-04-29
PE20150775A1 (es) 2015-05-21
EA026161B1 (ru) 2017-03-31
EP2912034A1 (en) 2015-09-02
IN2015DN00961A (enExample) 2015-06-12
EP2912034B1 (en) 2017-05-31
UA114649C2 (uk) 2017-07-10
MX2015002399A (es) 2015-06-10
KR20150075091A (ko) 2015-07-02
AU2013339607A1 (en) 2015-02-05
IL237331A0 (en) 2015-04-30
AR093168A1 (es) 2015-05-20
HK1207632A1 (en) 2016-02-05
JP2015535231A (ja) 2015-12-10
CN104781256A (zh) 2015-07-15
US20150246894A1 (en) 2015-09-03
CO7170170A2 (es) 2015-01-28
JP6216385B2 (ja) 2017-10-18
BR112015003996A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
US11084784B2 (en) ROR-gamma modulators and uses thereof
CN101679279B (zh) 作为5-ht6拮抗剂的磺酰吡唑啉甲脒衍生物
KR20130143138A (ko) 관절염 치료에 유용한 신규 이미다졸 유도체
JP6746614B2 (ja) ウレア誘導体、またはその薬理学的に許容される塩
JP2008528700A (ja) Ｐｐａｒモジュレーターとしての化合物および組成物
KR20050109583A (ko) 나트륨 채널 차단제로서의 바이아릴 치환된 트리아졸
US12391664B2 (en) GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
TW201702226A (zh) 尿素衍生物或其醫藥上可接受鹽
US11724997B2 (en) Compounds and compositions for treating conditions associated with APJ receptor activity
CN102015682A (zh) 作为肾素抑制剂的3,4-取代的哌啶衍生物
CN101304993A (zh) 作为ppar调节剂的化合物和组合物
CN104781256B (zh) 3，4‑双取代的噁唑烷酮衍生物和其作为钙激活的钾通道的抑制剂的用途
TW200922585A (en) Amino 1,2,4-triazole derivatives as modulators of mGluR5
KR100401314B1 (ko) 벤즈이미다졸 유도체 및 그의 약학적으로 허용되는 염
JP2021500416A (ja) 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
CN111630048B (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
HK1207632B (en) 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
WO2017008681A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
JP2025124692A (ja) 神経障害の治療に使用するための化合物
NZ614321B2 (en) Glycine transporter-inhibiting substances
CN101175731A (zh) 嘧啶羧酸衍生物及其用途
CN101939300A (zh) 作为大麻素cb1受体调节剂的4,5-二氢-(1h)-吡唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207632

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1207632

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170929

Termination date: 20191025